Levocarnitine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00583 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | KG + DL |
| 2 | brain small vessel disease 1 with or without ocular anomalies | KG + DL |
| 3 | diabetic nephropathy | KG + DL |
| 4 | rheumatoid arthritis | KG + DL |
| 5 | sclerosing cholangitis | KG + DL |
| 6 | gout | KG + DL |
| 7 | brachydactyly-syndactyly syndrome | KG + DL |
| 8 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 9 | congestive heart failure | KG + DL |
| 10 | hypoalphalipoproteinemia | KG + DL |
| 11 | pulmonary hypertension | KG + DL |
| 12 | homozygous familial hypercholesterolemia | KG + DL |
| 13 | acute pulmonary heart disease | KG + DL |
| 14 | kyphoscoliotic heart disease | KG + DL |
| 15 | chronic renal failure syndrome | KG + DL |
| 16 | chronic kidney disease | KG + DL |
| 17 | chronic pulmonary heart disease | KG + DL |
| 18 | end stage renal failure | KG + DL |
| 19 | malignant renovascular hypertension | KG + DL |
| 20 | malignant hypertensive renal disease | KG + DL |
| 21 | hypertensive disorder | KG + DL |
| 22 | pulmonary hypertension owing to lung disease and/or hypoxia | KG + DL |
| 23 | pulmonary hypertension with unclear multifactorial mechanism | KG + DL |
| 24 | Prinzmetal angina | KG + DL |
| 25 | intracerebral hemorrhage | KG + DL |
| 26 | Braddock syndrome | KG + DL |
| 27 | osteoarthritis susceptibility | KG + DL |
| 28 | cor pulmonale | KG + DL |
| 29 | paratenonitis | KG + DL |
| 30 | methemoglobinemia, alpha type | KG + DL |
| 31 | calcific tendinitis | KG + DL |
| 32 | hemoglobinopathy | KG + DL |
| 33 | obsolete hyperuricemia (disease) | KG + DL |
| 34 | obsolete familial combined hyperlipidemia | KG + DL |
| 35 | hyperthyroidism | KG + DL |
| 36 | Lesch-Nyhan syndrome | KG + DL |
| 37 | myositis | KG + DL |
| 38 | conjunctivitis | KG + DL |
| 39 | methemoglobin reductase deficiency | KG + DL |
| 40 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | KG + DL |
| 41 | methemoglobinemia | KG + DL |
| 42 | partial deletion of the short arm of chromosome 16 | KG + DL |
| 43 | multiple endocrine neoplasia | KG + DL |
| 44 | beta-thalassemia with other manifestations | KG + DL |
| 45 | WHIM syndrome | KG + DL |
| 46 | pyropoikilocytosis, hereditary | KG + DL |
| 47 | hemolytic anemia due to glucophosphate isomerase deficiency | KG + DL |
| 48 | peripheral arterial disease | KG + DL |
| 49 | Graves disease | KG + DL |
| 50 | peripheral vascular disease | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.